Barriers and Facilitators of Persistence With Adjuvant Osimertinib

Inclusion Criteria

• •For patient
• •Adults (≥18 years) with NSCLC who have received osimertinib as the 3rd generation EGFR-TKI adjuvant therapy and meet one of the following: Patients who received adjuvant osimertinib for less than 34 months and discontinued treatment (off treatment), or Patients who received adjuvant osimertinib for at least 34 months (either off treatment or still on treatment).
• •For off treatment patients, discontinuation or completion of osimertinib is required to occur within 6 months by screening.
• •Willing and able to provide informed consent, participate in an online or in-person qualitative interview, and permit audio recording for research purposes.
• •Licensed medical oncologists, thoracic surgeons, or pulmonologists with experience of prescribing osimertinib as adjuvant treatment and actively managing patients who will participate the interview.
• •Managed 5 patients with early-stage NSCLC receiving osimertinib within the past 6 months.
• •Holding a professional title equivalent to or higher than attending physician.
• •Willing and able to provide informed consent, participate in an online or in-person qualitative interview, and permit audio recording for research purposes.